Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Myocet · 1 trial · 1 indication
Recommended Doses of the combination treatment
% pathological Complete Response achieved according to Miller and Payne Criteria
| Arm | Type | Description |
|---|---|---|
| Myocet+Taxotere+Herceptin | EXPERIMENTAL | Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg |
| Name | Type | Description |
|---|---|---|
| Myocet | DRUG | Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles |
| Taxotere | DRUG | Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles |
| Herceptin | DRUG | Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles |
Inclusion Criteria: * Written informed consent. * Breast cancer stages II and IIIA with histological diagnoses by true-cut. * Breast cancer tumours overexpressing HER2neu, centrally confirmed by FISH. * No evidence of metastasis: bilateral mammography, thorax x-ray, computed tomography (CT)-scan or...
Top 20 of 92 competitors
Myocet is an investigational small molecule being studied for the treatment of breast cancer. It is being evaluated in the neoadjuvant setting for HER2 positive breast cancer patients, meaning it is given before surgery to shrink tumors. The drug is currently in Phase 1 clinical development.
Myocet is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting clinical research to evaluate the drug's safety and efficacy in breast cancer patients.
Myocet is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug remains under investigation for its potential use in breast cancer.
Myocet has been studied in one completed clinical trial, identified as NCT00129896. This Phase 1 trial, titled 'Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients,' enrolled 73 female participants aged 18 years and older in Spain.
Myocet is a small molecule being studied in breast cancer. The specific molecular target of Myocet has not been disclosed in the available clinical trial information. The completed trial focused on HER2 positive breast cancer patients, but the drug's mechanism of action is not specified.